Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study*
Main finding · In-hospital mortalityResult — go to the resultAdjusted odds ratio 0.88Authors' conclusion
Compared with the noncarbapenem broad-spectrum antibiotics, carbapenems as an initial therapy for sepsis were not associated with significantly lower mortality.
Study context
- Population
- Adults with sepsis, tertiary hospitals in Japan, 2006–2019
- Participants
- 7,392 adults
- Exposure
- Carbapenems vs Noncarbapenem
- Carbapenemsn = 3,547
- Noncarbapenemn = 3,845reference
- Outcome
- In-hospital mortality
Methodological detailsmulticentre, inverse probability treatment weighting using propensity scores
- Multicentre
- Inverse probability treatment weighting using propensity scores
Main finding
As reported in the abstract
Adjusted odds ratio
0.88
P = 0.108
Observational data: associations, not effects.
Further findings
In-hospital mortality, subgroups (septic shock, ICU, mechanical ventilation)
- Significant survival benefits suggested with carbapenems in septic shock, in ICUs, or with mechanical ventilation
- p for effect modifications: < 0.001, 0.014, and 0.105, respectively
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study*. Crit Care Med. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →